Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy.

ABSTRACT:

Purpose

A multimodal artificial intelligence (MMAI) biomarker was developed using clinical trial data from North American men with localized prostate cancer treated with definitive radiation, using biopsy digital pathology images and key clinical information (age, PSA, and T-stage) to generate prognostic scores. This study externally validates the biomarker in a prospective, real-world dataset of men who underwent radical prostatectomy (RP) for localized prostate cancer at a tertiary referral center in Sweden.

Experimental design

Association between the MMAI scores (continuous and categorical) and endpoints of interest was assessed with Fine-Gray and cumulative incidence analyses for biochemical recurrence (BCR) and logistic regression for adverse pathology (AP) at RP.

Re

SUBMITTER: Bjartell A 

PROVIDER: S-EPMC11995000 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature